Table 1. Demographic and clinical features in patients in patients exposed to TNF inhibitors.
| Patients’ features | RA (n = 3653) |
AS (n = 1150) |
PsA (n = 872) |
JIA (n = 124) |
Other spondyloarthritis (n = 54) |
Total (n = 5853) |
p* |
|---|---|---|---|---|---|---|---|
| Female | 3004 (82.2)* | 467 (40.6) | 446 (51.1) | 76 (61.2) | 29 (53.7) | 4022 (68.7) | <0,001 |
| Age (years)—mean (SD) | 52.7 (12.8)d | 42.8 (11.9)b | 47.7 (12.5)c | 13.1 (7.51)a | 44.0 (13.5)bc | 49.1 (14.1) | <0,001 |
| ≤65 years | 3039 (83.2) | 1112 (96.7)* | 798 (91.5)* | 124 (100)* | 51 (94.4) | 5124 (87.6) | |
| >65 years | 614 (16.8)* | 38 (3.3) | 74 (8.5) | 0 | 3 (5.6) | 729 (12.4) | |
| TNF inhibitors agent | 4212 | 1345 | 1030 | 151 | 60 | 6802 | |
| IFX | 430 (10.2)* | 113 (8.4) | 69 (6.6) | 7 (4.6) | 4 (6.6) | 623 (9.1) | 0,001 |
| ETN | 1441 (34.1) | 533 (39.2)* | 427 (41.4)* | 118 (78.1)* | 24 (40) | 2543 (37.3) | <0,001 |
| ADA | 1695 (40.2) | 696 (51.74)* | 529 (51.3)* | 28 (18.5) | 32 (53.3) | 2980 (43.8) | <0,001 |
| GOL | 483 (11.4)* | 3 (0.2) | 4 (0.3) | 2 (1.3) | 0 | 492 (7.2) | <0,001 |
| CZP | 163 (3.8)* | 0 | 1 (0.1) | 0 | 0 | 164 (2.4) | <0,001 |
| Number of patients per TNF inhibitors | 0,006 | ||||||
| 1 TNF inhibitors | 3090 (84.6)* | 953 (83) | 713 (81.7) | 92 (74.2) | 48 (89) | 4896 (83.6) | |
| 2 or more TNF inhibitors | 563 (15.4) | 197 (17) | 159 (18.3) | 32 (25.8)* | 6 (11) | 957 (16.4) | |
| Duration of TNF inhibitors therapy—mean years (SD) | 2.55 (2.03)b | 2.67 (1.71)b | 2.59 (1.85)b | 2.87 (2.27)b | 1.56(1.55)a | 2.58 (1.95) | <0,001 |
Abbreviations: RA, rheumatoid arthritis; AS, ankylosing spondylitis; PsA, psoriatic arthritis; JIA, juvenile idiopathic arthritis; TNF, tumor necrosis factor; IFX, infliximab; ETN, etanercept; ADA, adalimumab; GOL, golimumab; CZP, certolizumab pegol; SD, standard deviation;
* p significant
variables with letters not repeated = p significant